Bring new hope for patients with rheumatoid arthritis patients with 5 million RA patients, and the Junmeikang® Shanghai listing will end successfully

Physician News (Rong Media Reporter Guan Yanqing) Junmang Michael (Adamab), developed by Junshi Biological and Maiwei Biological Cooperation, has been successfully approved to be listed. On September 3, 2022, Maiwei Biological held the Jun Maikang®-Shanghai listing meeting. Many big coffees in the domestic rheumatism and immune fields gathered on the line to update and interpret clinical research data in rheumatism and skin fields. How to help doctors better choose topics such as biological preparations to discuss. At the invitation of Li Han, Vice President of Maiwei Bio, and Cong Xue, a national sales director, the guests including Professor He Dongyi, Professor Guanghua Hospital of Shanghai University of Traditional Chinese Medicine, Professor Zhu Xiaochun, First Affiliated Hospital of Wenzhou Medical University, and Shanghai Jiaotong University Medical College Professor Bao Chunde, Affiliated to Renji Hospital, Professor Xue Jing of the Second Affiliated Hospital of Zhejiang University, Professor Zhao Futao of the Ninth People's Hospital of Shanghai.

As the chairman of the conference, Professor He Dongyi first congratulated the successful listing of Junmeikang®, and also thanked the platform for building such a high -level academic exchanges for Maiwei's creatures. The latest progress of rheumatoid arthritis and rheumatoid diseases with secondary bone loose disease diagnosis and treatment "will soon be discussed and expressed expectations, and wish the conference a complete success!

Keynote Speech

During the meeting, many experts contributed wonderful keynote speeches and academic discussions, showing a wonderful academic feast.

2022 eular-rheumatoid arthritis treatment guide update interpretation

Professor Xue Jing of the Second Hospital of Zhejiang University

Professor Xue Jing introduced that in the treatment of rheumatoid arthritis (RA), the application of biologics brought significant clinical benefits to patients. Among them, tumor necrosis factor inhibitors (TNFI) and Janus kinase inhibitors (JAKI) have significant effects in inflammatory arthritis. Therefore, both are recommended by the American Rheumatology Society and the EULAR guide for treatment of severe RA patients in the treatment. In all TNFI, Ada Muzab's target treatment response rate and disease relief rate are the highest.

In terms of security, TNFI is better than Jaki. In the long run, Jaki increases the risk of cardiovascular and malignant tumors compared with TNFI. Since Jaki is a long -term use of RA patients, considering the above -mentioned risks must be continuously monitored. TNFI's safety is relatively good, and elderly patients can also use it with caution.

At the same time, Professor Xue Jing shared the latest research on the treatment of Adama mandarin combined with methotrexate in the treatment of RA. According to an international multi-center, random and open study (Miracle Research) for patients with poor response (MTX-IR) patients in Asia, for the patients of MTX-IR, Ada Mu Muzab The efficacy of combined with low -dose methotrexate is not inferior to the maximum tolerance dose of aminotreate, and has better safety.

RA's unsatisfactory treatment needs

Data Interpretation of Research Research Data in Phase III of Jun Maikang®

Professor Wan Weiguo, Huashan Hospital affiliated to Fudan University

"At present, there are 5 million RA patients in China, which are added 190,000 each year, and many patients have a heavy degree of disease, and the rate of compliance is not enough. The characteristics of the domestic RA can be summarized as "four" -the patients with many patients, many patients with delays, many patients with severe diseases, and many patients with complications, which brings great challenges to RA prevention and long -term prognosis.

The successful listing of Junmaikang® will provide new treatment hope for patients with RA. According to the clinical research data of the Re -Re -Re -Re -Re -Re -Re -Phase III, the clinical efficacy of Jun Maikang® and the original Research Pharmaceutical Merlot®, the ACR20 standard rate in the 24th week is similar. At the same time, Junmeikang® is similar to the characteristics, safety, and immunogenicity in pharmacokinetics. At present, the State Drug Administration has approved Junmang® to treat rheumatoid arthritis, anumous spinalitis and psoriasis.

Ada Mipida is used for the treatment of medium to severe psoriasis

Professor Yu Ning, Shanghai Dermatology Hospital

Professor Yu Ning introduced that psoriasis is a chronic, recurrence, inflammatory, and systemic diseases that are induced by genetic and environmental common effects. Its typical clinical manifestations are scales or plaques. more than half. At present, the treatment of psoriasis is still mainly based on traditional treatment. Patients with medium -weight patients have low curative effect, low treatment satisfaction, and has a greater impact on patients' physical and mental health and work and life.

TNF-α/IL-23/IL-17 is a key cytokines in the pathogenesis of psoriasis. Therefore, TNF-α/IL-23/IL-17 is also the main target of psoriasis biological treatment. Adamab is a TNF-α inhibitor, which can combine TNF competitively, thereby inhibiting TNF activity and regulating the inflammatory response process. It has been recommended by domestic and foreign authoritative guidelines for the treatment of medium-weight psoriasis.

Related studies have shown that Ada Mutter Monoparain has a fast effect, lasting efficacy, and good safety, which can significantly improve the quality of life and work efficiency of patients with medium -weight patients. It is a preferred biological agent for patients with medium -to -weight psoriasis.

"Defense" and "governance" of rheumatism and immune diseases secondary osteoporosis

Professor Xu Shengqian at the First Affiliated Hospital of Anhui Medical University

Professor Xu Shengqian said that immune cells and osteocytes are homologous, immune disorders can lead to bone metabolism disorders. Studies have shown that the incidence of abnormalities in bone metabolism is significantly higher than those of healthy people, and the assessment and treatment of secondary osteoporosis in rheumatism and immune diseases are often ignored, which will cause patient mortality, residual rate, and crispy fracture to occur. Risks such as rates increase. Clinical studies suggest that sufficient immunosuppressive treatment can prevent the decline in local and whole body bone mass. Therefore, patients with rheumatism and immune diseases, the use of TNF-α inhibitors and combined with conventional medication is the first step in preventing osteoporosis and fracture risks. For patients with low osteoporosis judgment standard T, anti -osteoporosis drugs should be used as soon as possible.

In addition, Professor Xu Shengqian emphasized that the secondary osteoporosis of rheumatism and immune diseases has not received enough attention. It is necessary to conduct osteoporosis as soon as possible for patients and early intervention.

Listing ceremony

At the end of the meeting, under the drive of Cong Xue, the chairman of the conference, Professor Zhu Xiaochun, Professor Zhu Xiaochun, and the national sales director, 22 experts followed the countdown to the listing ceremony to send blessings to the successful listing of Junmang®. Professor Zhu Xiaochun also sent a message in the summary of this conference, saying that the successful listing of Junmang® will bring the gospel to the majority of patients, and also provide a new treatment option for doctors. It can be seen that Jun Maikang's clinical equivalent with the original Ada Mibu is highly consistent. At the same time, with the improvement of craftsmanship, it will greatly reduce the adverse reactions of the drug. During the critical period of the booming development of domestic pharmaceutical companies, as a clinician, we should also strongly support domestically produced. I also hope that everyone can support Maiwei's creatures and support Junmang®!

Capture: Guan Yanqing

Edit: Guan Yanqing

- END -